AKTS
Aktis Oncology, Inc. · Healthcare · Market cap $1.1B
Insiders sold $3.2M net in the last 90 days ·3 sellers, 0 buyers· 1 of 5 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 24, 2026
Insider Buying
$114.3M
reported purchases (SEC code P)
Insider Selling
$3.2M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Latest filing
Sep 24, 2026
Czibere Akos
Aktis Oncology, Inc. (AKTS) has 12 SEC Form 4 filings (43 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Sep 24, 2026.
Inside the rolling window, 9 insiders at Aktis Oncology, Inc. reported 6 open-market purchases totaling $114.3M and 5 open-market sales totaling $3.2M. Insiders have net sold $3.2M over the trailing 6 months. The most recent open-market filing is a sale of 12,500 shares by Chief Medical Officer Czibere Akos, dated Sep 23, 2026, worth $259K.
- Industry:Biotechnology
- CEO:Matthew Roden
- Employees:79
- HQ:Boston, MA, US
- IPO:2026-01-09
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 12,500 | $259K | Sep 24 | — | SEC ↗ | |
| Director | Sale | 4,856 | $119K | Jul 22 | -20.5% | SEC ↗ | |
Herrmann KenFirst filing | Director | Sale | 3,065 | $77K | Jul 20 | -17.7% | SEC ↗ |
Ron-Bigger ShulamitFirst filing | Chief Operating Officer | Sale | 50,000 | $1.4M | Jul 10 | -29.3% | SEC ↗ |
Czibere AkosFirst filing | Chief Medical Officer | Sale | 50,000 | $1.4M | Jul 10 | -29.3% | SEC ↗ |
Foley ToddFirst filing | Director, 10% Owner | Purchase | 232,870 | $4.2M | Jan 14 | — | SEC ↗ |
MPM BIOVENTURES 2018, L.P.First filing | 10% Owner | Purchase | 1,112,777 | $20.0M | Jan 14 | — | SEC ↗ |
| 10% Owner | Purchase | 1,112,777 | $20.0M | Jan 14 | — | SEC ↗ | |
EcoR1 Capital, LLCFirst filing | Director | Purchase | 2,222,222 | $40.0M | Jan 12 | — | SEC ↗ |
Vida Ventures II, LLCFirst filing | 10% Owner | Purchase | 835,000 | $15.0M | Jan 12 | — | SEC ↗ |
Kim Helen SusanFirst filing | Director, 10% Owner | Purchase | 835,000 | $15.0M | Jan 12 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does AKTS have?
Aktis Oncology, Inc. (AKTS) has 12 SEC Form 4 filings (43 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Sep 24, 2026.
When was the most recent SEC Form 4 filing for AKTS?
The most recent Form 4 filing for AKTS on Tracefour is dated Sep 24, 2026.
What is the net insider flow at AKTS over the last 6 months?
Over the trailing 180 days, insiders at AKTS have net sold $3.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at AKTS in the current window?
Inside the rolling window, insiders at AKTS bought $114.3M and sold $3.2M based on SEC Form 4 filings.
Can I get alerts for AKTS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Aktis Oncology, Inc. (AKTS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Aktis Oncology, Inc. is in the Healthcare sector.